Genetic myostatin decrease in the golden retriever muscular dystrophy model does not significantly affect the ubiquitin proteasome system despite enhancing the severity of disease by Steven W Cotten et al.
Am J Transl Res 2014;6(1):43-53
www.ajtr.org /ISSN:1943-8141/AJTR1309009
Original Article
Genetic myostatin decrease in the golden retriever  
muscular dystrophy model does not significantly  
affect the ubiquitin proteasome system despite  
enhancing the severity of disease
Steven W Cotten1,3, Joe N Kornegay2, Daniel J Bogan3, Kristine M Wadosky3, Cam Patterson4,5, Monte S  
Willis3,5
1Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH, USA; 2Department of 
Veterinary Integrative Biosciences (Mail Stop 4458), College of Veterinary Medicine, Texas A&M University, College 
Station, TX, USA; 3Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, 
NC, USA; 4Departments of Medicine, Pharmacology, Cell and Developmental Biology, University of North Carolina, 
Chapel Hill, NC, USA; 5McAllister Heart Institute, University of North Carolina, Chapel Hill, USA
Received September 17, 2013; Accepted November 12, 2013; Epub December 1, 2013; Published January 1, 
2014
Abstract: Recent studies suggest that inhibiting the protein myostatin, a negative regulator of skeletal muscle mass, 
may improve outcomes in patients with Duchenne muscular dystrophy by enhancing muscle mass. When the dys-
trophin-deficient golden retriever muscular dystrophy (GRMD) dog was bred with whippets having a heterozygous 
mutation for the myostatin gene, affected GRMD dogs with decreased myostatin (GRippets) demonstrated an ac-
celerated physical decline compared to related affected GRMD dogs with full myostatin. To examine the role of the 
ubiquitin proteasome and calpain systems in this accelerated decline, we determined the expression of the mus-
cle ubiquitin ligases MuRF1, Atrogin-1, RNF25, RNF11, and CHIP: the proteasome subunits PSMA6, PSMB4, and 
PSME1: and calpain 1/2 by real time PCR in the cranial sartorius and vastus lateralis muscles in control, affected 
GRMD, and GRippet dogs. While individual affected GRMD and GRippet dogs contributed to an increased variability 
seen in ubiquitin ligase expression, neither group was significantly different from the control group. The affected 
GRMD dogs demonstrated significant increases in caspase-like and trypsin-like activity in the cranial sartorius; 
however, all three proteasome activities in the GRippet muscles did not differ from controls. Increased variability in 
calpain 1 and calpain 2 expression and activity in the affected GRMD and GRippet groups were identified, but no 
statistical differences from the control group were seen. These studies suggest a role of myostatin in the disease 
progression of GRMD, which does not significantly involve key components of the ubiquitin proteasome and calpain 
systems involved in the protein quality control of sarcomere and other structural skeletal muscle proteins.
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Introduction
Duchenne muscular dystrophy (DMD) is an 
inherited X-linked recessive disorder character-
ized by progressive muscle wasting first appear-
ing in early childhood. Muscle weakness occurs 
initially in the proximal limb muscles and subse-
quently affects more distal muscles [1]. A num-
ber of experimental therapies have been devel-
oped to stabilize the DMD myocyte by enhancing 
dystrophin expression; alternatively, therapies 
have been proposed to enhance the growth of 
muscle as well. Myostatin is a muscle protein 
that has inhibitory effects on muscle growth. 
Animals lacking myostatin have an enhanced 
musculature, including Belgian Blue cattle [2, 
3] and the “bully” whippet canine which is asso-
ciated with enhanced racing performance [4]. 
Given these findings, the inhibition of myostatin 
activity has been tested as a therapy in both 
mouse and dog models of DMD [5-8]. In con-
trast, human trials that have used myostatin 
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inhibition (MYO-029, a neutralizing antibody) 
have not been clearly beneficial and resulted in 
a few side effects [9, 10]. Given the therapeutic 
potential of myostatin, we crossed the golden 
retriever muscular dystrophy (GRMD) dog 
model [11] with the “bully whippet” canine hav-
ing a heterozygous mutation for myostatin [12] 
to elucidate the role of myostatin inhibition on 
the GRMD model. The resulting GRippets 
(Golden Retriever/Whippets) exhibited an 
accelerated decline in function, associated 
with differential muscle hypertrophy/atrophy, 
compared to muscular dystrophy littermates 
with full myostatin levels [13].
The primary phenotype of skeletal muscles in 
the GRMD model is skeletal muscle atrophy, 
with the exception of certain muscles such as 
the cranial sartorius muscle, which exhibits a 
true hypertrophy [14, 15]. A number of recent 
studies have identified a role for the ubiquitin 
proteasome and calpain systems in the role of 
mediating skeletal muscle atrophy [16-18]. To 
identify the role of the ubiquitin proteasome 
and calpain systems in the accelerated demise 
of dogs with decreased myostatin (GRMD/Mstn 
+/-), skeletal muscle was biopsied and analyzed 
for expression and activity of ubiquitin protea-
some components. Surprisingly, myostatin inhi-
bition had very limited effects on the protea-
some and calpain systems in skeletal muscle, 
indicating other mechanisms may mediate dif-
ferential muscle involvement and associated 
accelerated demise.
Materials and methods
Creation of golden retriever muscular dystro-
phy / myostatin-deficient whippet (GRippet) 
dogs
The University of North Carolina-Chapel Hill 
GRMD colony derived from the original founder 
[19] was used in these studies. Dogs were 
cared for according to the principles outlined in 
the National Research Council Guide for the 
Care and Use of Laboratory Animals. The GRMD 
status was identified based on the elevation of 
serum creatinine kinase (CK) and characteristic 
clinical signs. The genotype was confirmed by 
PCR analysis if the CK results were ambiguous. 
These studies were approved by the University 
of North Carolnia Institutional Animal Care and 
Use Committee (IACUC #11-110, “Cross 
Breeding of Muscular Dystrophy and Myostatin-
Null Dogs”).
Whippet dogs homozygous for the myostatin-
null allele (Mstn-/-) have gross muscle enlarge-
ment, while Mstn heterozygotes (+/-) have inter-
mediate muscle mass [4]. Heterozygous 
myostatin (Mstn +/-) semen was used to artifi-
cially inseminate an obligate GRMD carrier to 
generate an F1 generation (Table 1). Of the 
resulting offspring, Speedy, a GRMD and Mstn 
+/- carrier was then bred to a GRMD male to 
produce an F2 generation. DNA was isolated 
from buccal swab samples to assign genotypes 
for myostatin status. Genotyping confirmed the 
two base pair deletion at nucleotides 939 and 
940 previously reported [4].
Muscle biopsies
Dogs were anesthetized using conventional 
preanesthetic drugs, propofol (normal dogs 
only), and sevoflurane. The muscle(s) were 
exposed sharply at surgery to allow removal of 
a sample of approximately 1 X 0.5 X 0.5 cm, 
snap frozen in liquid nitrogen, and stored at 
-80°C for further processing.
Gene expression analyses
Frozen tissue was homogenized using a glass 
homogenizer (Kontes, USA) in 600 µl of RTL 
Buffer from the Qiagen RNeasy Kit (Valencia, 
CA) and RNA purified according to manufactur-
ers’ instructions. Purified RNA was eluted in 50 
µl of RNase free water and the concentration 
measured using a Nanodrop Spectrophotometer 
Table 1. GRMD-Myostatin Status 
Dog Name Gender GRMD Status Myostatin Status
F1 Generation (Mstn +/- Male x GRMD Carrier)
Racer Male Normal Normal
Dash Male Affected Heterozygote
Flash Male Affected Normal
Speedy Female Carrier Heterozygote
Lightning Female Carrier Normal
Zippy Female Normal Heterozygote
F2 Generation (GRMD Male x Speedy)
Endora Female Carrier Normal
Esmerelda Female Carrier Heterozygote
Samantha Female Affected Normal
Tabitha Female Affected Heterozygote
Hagatha Female Affected Normal
Derrwood Male Affected Heterozygote
Abner Male Affected Heterozygote
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(Thermo Fisher Scientific, Inc., Waltham, MA). 
Fifty ng of RNA was used for cDNA synthesis 
using the Life Technologies High Capacity cDNA 
Reverse Transcription kit (Carlsbad, CA). Fifty μl 
cDNA synthesis reactions were performed for 
each RNA template (1X RT Buffer, 4 mM dNTPs, 
1X random primers, 250 units RNAse inhibitor, 
125 units of Multiscribe reverse transcriptase). 
The reactions were cycled for 25°C for 10 min-
utes, 37°C for 120 minutes, 85°C for 5 sec-
onds, then cooled to 4°C. Gene expression was 
evaluated using TaqMan Real Time PCR Master 
Mix using canine specific probes for calpain 1 
(Cf02704115_m1), calpain 2 (Cf02645870_
m1), STUB1 (aka CHIP) (Cf02644017_m1), 
muscle atrophy F-box (aka Atrogin-1) (FBXo32; 
Cf02667148_mi), MDM2 (Cf026759237_m1), 
muscle ring finger protein 1 (MuRF1; Cf026- 
49993_mi), proteasome subunit alpha type 6 
(PSMA6; Cf02666165_g1), proteasome sub-
unit beta type 4 (PSMB4; Cf01123846_m1), 
proteasome subunit activator type 1 (PSME1; 
Cf02646187_g1), Ubiquitin (UbB, Mm0162- 
2233_g1), UNC4/5 homolog E2 (UBE2D1, 
Cfr02657121_m1), UBC9 homolog E2 (UBE2I), 
dystrophin (DMD, Cf02623221_m1), myostatin 
(MSTN Cf02704228_m1), ring finger 11 (RNF- 
11, Cf02708288_s1), ring finger 25 (RNF25, 
Cf02713677_m1), ring finger 115 (RNF115, 
Cf02658284_m1), and analyzed using an 
Applied Biosystems 7500 series real time PCR 
machine (Applied Biosystems, Inc., Carlsbard, 
CA). The relative expression of the genes were 
normalized to 18S using the delta-delta Ct 
(ΔΔCt) method.
Proteasome activity determination using fluo-
rogenic substrates
Chymotrypsin-like, Trypsin-like, and Caspase-
like proteasome activities were determined by 
measuring the rate by which activity-specific 
fluorogenic substrates were cleaved. Briefly, tis-
sue was homogenized in lysis buffer (250 mM 
Sucrose, 50 mM Tris pH 7.5, 5 mM MgCl2, 0.5 
mM EDTA, 1 mM DTT, 2 mM ATP, 0.03% 
Digitonin) using a glass homogenizer (Kontes, 
USA). The lysate was centrifuged at 12,000 
rpm and the supernatant stored at -80°C. 25 
μg of lysate was then assayed in triplicate for 
the rate of cleavage of peptide substrates for 
Chymotrypsin-like (Suc-Leu-Leu-Val-Tyr-AMC), 
Trypsin-like (Ac-Arg-Leu-Arg-AMC), and Capase-
like (Z-Leu-Leu-Glu-AMC) activities using com-
mercially available substrates (Enzo Life 
Sciences, Farmingdale, NY). Twenty-five µg of 
lysate was combined with 50 µl of 2X protea-
some assay buffer plus 150 µM of peptide sub-
strate. Reactions were incubated at 37°C and 
fluorescence measured (excitation 360 nm 
emission 465 nm) every 2 minutes for 80 min-
utes in a Wallac Victor 2 spectrophotometer 
(excitation 355 nm, emission 460 nm). Parallel 
samples were pre-incubated with the protea-
some inhibitor epoxomicin (20 μM) for 30 min 
at 37°C, to determine the non-specific sub-
strate hydrolysis. These fluorescence units 
were then subtracted from each measure- 
ment.
Calpain 1 / Calpain 2 activity assay
Calpain 1 / Calpain 2 activities were deter-
mined using the Sensolyte ® AMC Calpain 
Activity Fluorometric Assay kit according to the 
manufacturer’s instructions (Sensolyte AMC 
Calpain Assay Component C, Freemont, CA). 
The Calpain 1 / Calpain 2 activity was deter-
mined by the hydrolysis of the fluorogenic pep-
tide substrate succinyl-leucine-leucine-valine-
tyrosine-4-methyl-7-courmarylamide (Suc-LLVY- 
AMC). Briefly, tissues were homogenized in lysis 
buffer using a glass homogenizer (Kontes, 
USA), the lysate centrifuged at 12,000 rpm for 
10 minutes, and the supernatant stored at 
-80°C. 25 μg of lysate was incubated with the 
fluorogenic peptide substrate succinyl-leucine-
leucine-valine-tyrosine-4-methyl-7-courmaryl-
amide (Suc-LLVY-AMC) for 1 hour at 37°C. 
Fluorescence was measured using a Perkin 
Elmer Wallac Victor II Multi-label Microplate 
reader (excitation 350 nm, emission 460 nm, 
Waltham, MA).
Statistical analyses
Statistical analyses were performed using 
SigmaPlot 11 (Systat Software Inc, San Jose 
California). A Rank-Sum test was performed to 
compare the three groups as the data were 
determined to be non-parametric using a nor-
mality test and (when appropriate) an equal 
variance. Statistical significance was deter-
mined if p≤0.05.
Results
Semen collected from a myostatin heterozy-
gous whippet sire was used to artificially insem-
inate an obligate GRMD carrier, producing an 
initial litter that included Racer, Dash, and 
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Figure 1. Ubiquitin ligases and ubiquitin components expression in skeletal muscle from control, affected GRMD, and GRMD/Myostatin +/- (GRippet) dogs. A. Ubiq-
uitin ligases implicated in skeletal muscle mass regulation and cell survival. B. Complementing ubiquitin and ubiquitin conjugating enzymes (E2) involved in protein 
quality control systems in striated muscle.
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Figure 2. Analysis of proteasome subunit expression and activities in skeletal muscle from control, affected GRMD, and GRMD/Myostatin +/- (GRippet) dogs. A. 
mRNA expression of proteasome subunits PSMA6, PSMB4, and PSME1 and B. parallel proteasome activities: chymotrypsin, caspase-like activity, and trypsin activ-
ity.
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Flash (Table 1). A second litter was generated 
using semen from a GRMD male and a female 
GRMD carrier/myostatin heterozygote (Mstn 
+/-) from litter 1 (Speedy) generating a second 
litter. The resulting dogs were classified as non-
dystrophic controls (either normal, GRMD carri-
ers, or Mstn heterogygous), GRMD affected-
Mstn-myostatin homozygote (GRMD) and 
GRMD affected/Myostatin deficient (GRMD/
Myostatin +/-; GRippets) based on their geno-
typing (Table 1). For sake of data analysis, four 
GRippets (Dash, Derrwood, Abner, Tabitha), 
three GRMD dogs (Flash, Hagatha, Samantha), 
and three controls (Racer, Esmerelda, Endora) 
were assessed. Previous studies from our 
group have identified that the cranial sartorius 
(CS) undergoes true hypertrophy, while most 
other muscles such as the vastus lateralis (VL) 
atrophy [14, 15]. The CS is a hip flexor, while the 
VL extends the stifle (knee). Therefore, we 
investigated the ubiquitin proteasome and cal-
pain systems in the CS and VL from these three 
phenotypically distinct muscles.
GRMD status and myostatin expression does 
not affect the expression of the ubiquitin 
ligases MuRF1, Atrogin-1, CHIP, and MDM2 or 
other ubiquitin components
Real time PCR analysis of muscle specific ubiq-
uitin ligase expression was performed on CS 
and VL in control, GRMD affected, and GRMD/
Myostatin +/- GRippet dogs. Using non-para-
metric statistical analyses, no significant differ-
ences in MuRF1, Atrogin-1, CHIP, and MDM2 
expression were identified among the three 
groups (Figure 1A) in either CS or VL muscles. 
However, 1 of 4 dogs (Dash) in the GRMD/
Myostatin +/- group had highly increased 
MuRF1 and Atrogin-1 expression, which ac- 
counted for variability seen in that group (Figure 
1A). The ubiquitin, UBC 4/5, and UBC9 mRNA 
were also not significantly different among the 
three groups (Figure 1B). However, the median 
UBC9 was decreased in both GRMD and 
GRMD/Myostatin +/- groups.
Muscle specific expression of proteasome 
components PSMA6, PSMB4, PSME1 and 
proteasome activities are largely unaffected by 
GRMD and myostatin levels
Real time PCR analysis of the mRNA expression 
of MSMA6, PSMB4, and PSME1 in CS and VL in 
control, GRMD affected, and GRMD/Myostatin 
+/- dogs demonstrated no significant differenc-
es (Figure 2A). There were consistent increases 
in all three proteasome components in individ-
ual GRMD/Myostatin +/- dogs, but only in 1-2 of 
the four dogs in this group, so these changes 
did not reach statistical significance. We next 
assayed the chymotrypsin, caspase-like, and 
trypsin proteasome activities in the same mus-
cle biopsies and identified a general increase in 
all three activities in both CS and VL in the 
GRMD group (Figure 2B). The GRMD group with 
decreased myostatin (Myo +/-) also generally 
had a decrease in all three activities; the only 
significant changes that were identified were in 
the CS caspase-like and trypsin activities 
(Figure 2B, bottom left 2 panels).
Muscle specific calpain 1 and 2 expression 
and calpain activity
No differences in calpain 1 or calpain 2 mRNA 
expressions were identified between GRMD 
and GRMD/Myostatin +/- groups in either the 
CS or VL (Figure 3A). Increased variability in 
both of these enzymes was seen in the GRMD 
and GRMD/myostatin +/- groups. The calpain 1 
and calpain 2 activities were not significantly 
different between groups either, although the 
GRMD/Myostatin +/- group had more variability 
due to a subset of dogs.
Discussion
Experimentally, dystrophin-deficient mdx mice 
lacking myostatin or with myostatin inhibited 
post-natally appear to have a less severe phe-
notype [5, 20]. This has led to the interest in 
therapies that inhibit myostatin to promote 
muscle grown and possibly improve function in 
muscular dystrophy [21, 22]. In other dystro-
phic mouse models lacking myostatin, the 
results have varied with some mice having 
increased morbidities [23], including abnormal-
ities in muscle tendons from Mstn-/- mice [24]. 
In the present study, the phenotype of GRMD 
dogs with decreased myostatin (Myostatin +/- 
GRippets) have disproportionate muscle 
effects and increased phenotype severity [13], 
consistent with some murine studies. 
Since a number of recent studies have suggest-
ed that myostatin regulates various compo-
nents of the ubiquitin proteasome [25-27] and 
calpain activity has been linked to muscular 
dystrophy severity [28, 29], we investigated 
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both systems in the GRippet model. While 
recent studies have identified that some GRMD 
muscle types (e.g. gastrocnemius, anterior tibi-
alis) have increased proteasome and calpain 
activity, these changes were much less uniform 
than that previously identified in mouse studies 
[30]. When we investigated how decreased 
myostatin affected these same ubiquitin pro-
teasome system and calpain expression and 
activity, we identified fewer changes in the 
GRMD with decreased myostatin despite the 
worse phenotype [13]. The results largely indi-
cate that the major components of the ubiqui-
tin proteasome system, including the ubiquitin 
ligases MuRF1, Atrogin-1, CHIP, and MDM2 
found in skeletal muscle are not consistently 
affected in the cranial sartorius and vastus 
lateralis in dogs with GRMD and GRMD with 
myostatin deficiency compared to controls. 
While the expression of the proteasome com-
ponents PSMA6, PSMB4, and PSME1 in the CS 
and VL muscles did not differ among groups, 
Figure 3. Analysis of the calpain enzymatic system expression and activities in skeletal muscle from control, af-
fected GRMD, and GRMD/Myostatin +/- (GRippet) dogs. A. mRNA expression of calpain 1 and calpain 2 and B. 
Calpain 1 / Calpain 2 combined activities.
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the GRMD group with decreased myostatin 
(Myostatin +/-) generally had a decrease in all 
three activities, which were significant for the 
CS caspase-like and trypsin activity. Changes 
in the UPS and calpain systems were minor at 
most. Therefore, our data do not support a role 
for these systems in differential muscle involve-
ment in the GRippet model.
Multiple studies have reported that reducing 
myostatin activity has apparent therapeutic 
benefit in both mouse and dog models of DMD 
[5-8]. However, phase II human clinical trials for 
ACE-031, a humanized antibody mimicking the 
myostatin receptor ActRIIB to inhibit myostatin 
activity were stopped due to unfavorable safety 
profiles [31]. Additionally, previous human clini-
cal trials of adult muscular dystrophy patients 
using myostatin neutralizing antibodies also 
demonstrated no beneficial outcomes for mus-
cle strength, function, or growth [10]. Recent 
studies have also demonstrated that the elimi-
nation of myostatin in other muscular dystro-
phy models (laminin-deficiency) has proven to 
increase postnatal lethality [23]. The GRippet 
model similarly appears to be made worse 
when myostatin is reduced [13]. This clinical 
severity may result from both direct and indi-
rect effects on the adult skeletal muscles 
investigated. Despite myostatin’s possible reg-
ulation of the ubiquitin proteasome systems 
[25-27] and the link of calpain activity to mus-
cular dystrophy severity [28, 29], these sys-
tems do not appear to be dysregulated exten-
sively or parallel the severe differences in 
phenotype that are observed with GRMD with 
myostatin haploinsufficiency.
Recent studies have identified that myostatin 
mRNA is reduced in DMD patients [32], with 
the processing and maturation of myostatin 
protein inhibited in some patients [33]. 
Decreased myostatin in the mdx mouse model 
has also been reported [34]. In the present 
study, we similarly identified that myostatin was 
decreased in both the GRMD and GRMD/Mstn 
(+/-) groups significantly in the CS (p=0.034), 
but not in the VL (p=0.291), indicating that 
these changes may be muscle specific (Figure 
4). Unlike myostatin mRNA levels, dystrophin 
levels in the CS and VL were not significantly 
different between the dystrophic and control 
dog groups. This is inconsistent with the gener-
ally accepted concept that mRNA levels are 
reduced in DMD due to of nonsense mediated 
decay [35, 36]. Dystrophin mRNA levels were 
Figure 4. mRNA expression of myostatin and dystrophin from control, affected GRMD, and GRMD/Myostatin +/- 
(GRippet) dogs. 
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also reduced in initial studies of muscle from 
mdx mice [37] and GRMD dogs [38]. However, a 
recent RT-qPCR study showed that dystrophin 
mRNA levels in mdx muscles were comparable, 
if not even higher, than those in wild type mice 
[39]. This study also showed that mRNA expres-
sion was greater at the 5’ versus 3’ end and 
that this imbalance played a major role in dys-
trophin expression. For sake of canine data pre-
sented here, the dystrophin probe used identi-
fied a region spanning exon 32-33, which would 
be relatively more 5’, which may explain the 
unexpected DMD mRNA levels detected.
We used the GRMD model of DMD as its sever-
ity and variability parallels the human disease 
to a much greater extent than mouse models 
[14, 19, 30, 38]. Despite the proposed utility of 
proteasome inhibitors in DMD, we identified 
that less than ½ of the muscles assayed had 
increases in proteasome activity and only ½ 
had increased calpain activity [30]. Similarly, 
the transcriptional regulation of the ubiquitin 
proteasome system in skeletal muscle was 
largely unaffected [30]. Since both the ubiqui-
tin proteasome and calpain systems are crucial 
mediators of skeletal muscle atrophy, we antici-
pated that the GRMD/Myo +/- group would 
have an enhanced UPS and calpain activities. 
However, there were no clear consistent 
increases in the regulation and activity of the 
UPS and calpain systems, indicating that other 
mechanisms were likely involved in the dispro-
portionate muscle involvement and associated 
accelerated decline seen in the GRippet group.
Acknowledgements
The work was sponsored by the Co-operative 
Program in Translational Research: Proposal 
for Establishment of the National Center for 
Canine Models of Duchenne Muscular Dystro- 
phy (NCDMD) (1U24NS059696-01A1; NINDS) 
(to J.K.), the Muscular Dystrophy Association 
Infrastructure Grant to the Translational Re- 
search Advisory Committee (to J.K.), the Na- 
tional Institutes of Health (1R01HL104129-01) 
(to M.W.), a Fellowship from the Jefferson-Pilot 
Corporation (to M.W.), and the Leducq Foun- 
dation (to C.P. and M.W.).
Disclosure of conflict of interest
The authors do not have any conflicts of inter-
est to disclose.
Abbreviations
AAV, adeno-associated virus; CS, Cranial sarto-
rius; DMD, Duchenne muscular dystrophy; 
GRMD, golden retriever muscular dystrophy; 
MDM2, murine double mutant 2; MuRF1, mus-
cle ring finger-1; VL, vastus lateralis.
Address correspondence to: Dr. Monte S Willis, 
McAllister Heart Institute, Department of Pathology 
& Laboratory Medicine, University of North Carolina, 
111 Mason Farm Road, 2240B MBRB, Chapel Hill, 
NC 27599-7525, USA. Tel: 919-843-1938; Fax: 
919-843-4585; E-mail: monte_willis@med.unc.edu
References
[1] Do T. Orthopedic management of the muscular 
dystrophies. Curr Opin Pediatr 2002; 14: 50-
53.
[2] McPherron AC and Lee SJ. Double muscling in 
cattle due to mutations in the myostatin gene. 
Proc Natl Acad Sci U S A 1997; 94: 12457-
12461.
[3] Grobet L, Martin LJ, Poncelet D, Pirottin D, 
Brouwers B, Riquet J, Schoeberlein A, Dunner 
S, Menissier F, Massabanda J, Fries R, Hanset 
R and Georges M. A deletion in the bovine myo-
statin gene causes the double-muscled pheno-
type in cattle. Nat Genet 1997; 17: 71-74.
[4] Mosher DS, Quignon P, Bustamante CD, Sutter 
NB, Mellersh CS, Parker HG and Ostrander EA. 
A mutation in the myostatin gene increases 
muscle mass and enhances racing perfor-
mance in heterozygote dogs. PLoS Genet 
2007; 3: e79.
[5] Wagner KR, McPherron AC, Winik N and Lee 
SJ. Loss of myostatin attenuates severity of 
muscular dystrophy in mdx mice. Ann Neurol 
2002; 52: 832-836.
[6] Bogdanovich S, Krag TO, Barton ER, Morris LD, 
Whittemore LA, Ahima RS and Khurana TS. 
Functional improvement of dystrophic muscle 
by myostatin blockade. Nature 2002; 420: 
418-421.
[7] Qiao C, Li J, Zheng H, Bogan J, Li J, Yuan Z, 
Zhang C, Bogan D, Kornegay J and Xiao X. Hy-
drodynamic limb vein injection of adeno-asso-
ciated virus serotype 8 vector carrying canine 
myostatin propeptide gene into normal dogs 
enhances muscle growth. Hum Gene Ther 
2009; 20: 1-10.
[8] Bish LT, Sleeper MM, Forbes SC, Morine KJ, 
Reynolds C, Singletary GE, Trafny D, Pham J, 
Bogan J, Kornegay JN, Vandenborne K, Walter 
GA and Sweeney HL. Long-term systemic myo-
statin inhibition via liver-targeted gene transfer 
in golden retriever muscular dystrophy. Hum 
Gene Ther 2011; 22: 1499-1509.
Regulation of the UPS by myostatin in muscular dystrophy
52 Am J Transl Res 2014;6(1):43-53
[19] Kornegay JN, Tuler SM, Miller DM and Levesque 
DC. Muscular dystrophy in a litter of golden re-
triever dogs. Muscle Nerve 1988; 11: 1056-
1064.
[20] Benvenuti F, Lattanzi F, De Gori A and Tarli P. 
[Activity of some derivatives of palmitoyletha-
nolamide on carragenine-induced edema in 
the rat paw]. Boll Soc Ital Biol Sper 1968; 44: 
809-813.
[21] Bradley L, Yaworsky PJ and Walsh FS. Myo-
statin as a therapeutic target for musculoskel-
etal disease. Cell Mol Life Sci 2008; 65: 2119-
2124.
[22] Patel K and Amthor H. The function of Myo-
statin and strategies of Myostatin blockade-
new hope for therapies aimed at promoting 
growth of skeletal muscle. Neuromuscul Dis-
ord 2005; 15: 117-126.
[23] Li ZF, Shelton GD and Engvall E. Elimination of 
myostatin does not combat muscular dystro-
phy in dy mice but increases postnatal lethali-
ty. Am J Pathol 2005; 166: 491-497.
[24] Mendias CL, Bakhurin KI and Faulkner JA. Ten-
dons of myostatin-deficient mice are small, 
brittle, and hypocellular. Proc Natl Acad Sci U S 
A 2008; 105: 388-393.
[25] Lokireddy S, Wijesoma IW, Bonala S, Wei M, 
Sze SK, McFarlane C, Kambadur R and Shar-
ma M. Myostatin is a novel tumoral factor that 
induces cancer cachexia. Biochem J 2012; 
446: 23-36.
[26] Lokireddy S, Wijesoma IW, Sze SK, McFarlane 
C, Kambadur R and Sharma M. Identification 
of Atrogin-1 targeted proteins during the Myo-
statin-induced skeletal muscle wasting. Am J 
Physiol Cell Physiol 2012; 303: C512-29.
[27] Lokireddy S, Mouly V, Butler-Browne G, Gluck-
man PD, Sharma M, Kambadur R and McFar-
lane C. Myostatin promotes the wasting of hu-
man myoblast cultures through promoting 
ubiquitin-proteasome pathway-mediated loss 
of sarcomeric proteins. Am J Physiol Cell Physi-
ol 2011; 301: C1316-1324.
[28] Saez ME, Ramirez-Lorca R, Moron FJ and Ruiz 
A. The therapeutic potential of the calpain fam-
ily: new aspects. Drug Discov Today 2006; 11: 
917-923.
[29] Gailly P, De Backer F, Van Schoor M and Gillis 
JM. In situ measurements of calpain activity in 
isolated muscle fibres from normal and dystro-
phin-lacking mdx mice. J Physiol 2007; 582: 
1261-1275.
[30] Wadosky KM, Li L, Rodriguez JE, Min JN, Bogan 
D, Gonzalez J, Patterson C, Kornegay JN and 
Willis M. Regulation of the calpain and ubiqui-
tin-proteasome systems in a canine model of 
muscular dystrophy. Muscle Nerve 2011; 44: 
553-562.
[31] Seehra J. Inhibition of the myostatin pathway 
for treatment of neuromuscular diseases. MDA 
[9] Krivickas LS, Walsh R and Amato AA. Single 
muscle fiber contractile properties in adults 
with muscular dystrophy treated with MYO-
029. Muscle Nerve 2009; 39: 3-9.
[10] Wagner KR, Fleckenstein JL, Amato AA, Barohn 
RJ, Bushby K, Escolar DM, Flanigan KM, 
Pestronk A, Tawil R, Wolfe GI, Eagle M, Flor-
ence JM, King WM, Pandya S, Straub V, Juneau 
P, Meyers K, Csimma C, Araujo T, Allen R, Par-
sons SA, Wozney JM, Lavallie ER and Mendell 
JR. A phase I/IItrial of MYO-029 in adult sub-
jects with muscular dystrophy. Ann Neurol 
2008; 63: 561-571.
[11] Prattis SM, Horton SB, van Camp SD and Ko-
rnegay JN. Immunohistochemical detection of 
neural cell adhesion molecule and laminin in 
X-linked dystrophic dogs and mdx mice. J 
Comp Pathol 1994; 110: 253-266.
[12] Shelton GD and Engvall E. Gross muscle hyper-
trophy in whippet dogs is caused by a mutation 
in the myostatin gene. Neuromuscul Disord 
2007; 17: 721-722.
[13] Kornegay JN, Bogan DJ, Bogan JR, Dow JL, 
Wang J, Fan Z, Warsing LC, Grange RW, Styner 
MA, Wagner KR. Disproportionate Muscle Hy-
pertrophy Increases Phenotype Severity in 
Myostatin-Heterozygous GRMD (GRippet) 
Dogs. EMBO Workshop - Molecular Mecha-
nisms of Muscle Growth and Wasting in Health 
and Disease. Ascona, Switzerland. 2011 Sep 
18.
[14] Kornegay JN, Cundiff DD, Bogan DJ, Bogan JR 
and Okamura CS. The cranial sartorius muscle 
undergoes true hypertrophy in dogs with gold-
en retriever muscular dystrophy. Neuromuscul 
Disord 2003; 13: 493-500.
[15] Liu JM, Okamura CS, Bogan DJ, Bogan JR, 
Childers MK and Kornegay JN. Effects of pred-
nisone in canine muscular dystrophy. Muscle 
Nerve 2004; 30: 767-773.
[16] Bodine SC, Latres E, Baumhueter S, Lai VK, 
Nunez L, Clarke BA, Poueymirou WT, Panaro FJ, 
Na E, Dharmarajan K, Pan ZQ, Valenzuela DM, 
DeChiara TM, Stitt TN, Yancopoulos GD and 
Glass DJ. Identification of ubiquitin ligases re-
quired for skeletal muscle atrophy. Science 
2001; 294: 1704-1708.
[17] Park S, Nozaki K, Guyton MK, Smith JA, Ray SK 
and Banik NL. Calpain inhibition attenuated 
morphological and molecular changes in skel-
etal muscle of experimental allergic encepha-
lomyelitis rats. J Neurosci Res 2012; 90: 2134-
45.
[18] Fareed MU, Evenson AR, Wei W, Menconi M, 
Poylin V, Petkova V, Pignol B and Hasselgren 
PO. Treatment of rats with calpain inhibitors 
prevents sepsis-induced muscle proteolysis in-
dependent of atrogin-1/MAFbx and MuRF1 
expression. Am J Physiol Regul Integr Comp 
Physiol 2006; 290: R1589-1597.
Regulation of the UPS by myostatin in muscular dystrophy
53 Am J Transl Res 2014;6(1):43-53
[37] Chamberlain JS, Pearlman JA, Muzny DM, 
Gibbs RA, Ranier JE, Caskey CT and Reeves AA. 
Expression of the murine Duchenne muscular 
dystrophy gene in muscle and brain. Science 
1988; 239: 1416-1418.
[38] Sharp NJ, Kornegay JN, Van Camp SD, Herbst-
reith MH, Secore SL, Kettle S, Hung WY, Con-
stantinou CD, Dykstra MJ, Roses AD and 
Bartlett RJ. An error in dystrophin mRNA pro-
cessing in golden retriever muscular dystrophy, 
an animal homologue of Duchenne muscular 
dystrophy. Genomics 1991; 13: 115-121.
[39] Spitali P, van den Bergen JC, Verhaart IE, 
Wokke B, Janson AA, van den Eijnde R, den 
Dunnen JT, Laros JF, Verschuuren JJ, ‘t Hoen 
PA and Aartsma-Rus A. DMD transcript imbal-
ance determines dystrophin levels. FASEB J 
2013 Aug 23; [Epub ahead of print].
National Scientific Conference: Neuromuscu-
lar Therapeutic Strategies: Overcoming the 
Barriers from Microscope to Marketplace. Las 
Vegas, NV. 2011 Mar 15.
[32] Chen YW, Nagaraju K, Bakay M, McIntyre O, 
Rawat R, Shi R and Hoffman EP. Early onset of 
inflammation and later involvement of TGFbeta 
in Duchenne muscular dystrophy. Neurology 
2005; 65: 826-834.
[33] Zhang Y, Chen Y, Chen JW and Zhu DH. [Altered 
expression of myostatin gene in the progres-
sive muscular dystrophy patients]. Yi Chuan 
Xue Bao 2005; 32: 779-783.
[34] Tseng BS, Zhao P, Pattison JS, Gordon SE, 
Granchelli JA, Madsen RW, Folk LC, Hoffman 
EP and Booth FW. Regenerated mdx mouse 
skeletal muscle shows differential mRNA ex-
pression. J Appl Physiol 2002; 93: 537-545.
[35] Chen YW, Zhao P, Borup R and Hoffman EP. Ex-
pression profiling in the muscular dystrophies: 
identification of novel aspects of molecular 
pathophysiology. J Cell Biol 2000; 151: 1321-
1336.
[36] Pescatori M, Broccolini A, Minetti C, Bertini E, 
Bruno C, D’Amico A, Bernardini C, Mirabella M, 
Silvestri G, Giglio V, Modoni A, Pedemonte M, 
Tasca G, Galluzzi G, Mercuri E, Tonali PA and 
Ricci E. Gene expression profiling in the early 
phases of DMD: a constant molecular signa-
ture characterizes DMD muscle from early 
postnatal life throughout disease progression. 
FASEB J 2000; 21: 1210-1226.
